Europe Orders 200 Million Vaccine Doses

New York-based Pfizer Inc. and its German partner BioNTech SE announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate to the European Union Member States. The vaccine deliveries are anticipated to start by the end of 2020, subject to clinical success and regulatory authorization.

According to the press statement on November 10, 2020, the European Commission has an option to purchase an additional 100 million BNT162b2 vaccine doses.

This mRNA SARS-CoV-2 coronavirus preventive vaccine candidate is in various late-stage clinical trials.